Wave will soon report key early-stage data with its exon-skipping DMD candidate suvodirsen but, unlike Sarepta, the group is starting its confirmatory trial before…
Impressive results in lung cancer with Eli Lilly’s Ret inhibitor set the stage for approval next year, but Blueprint is not far behind.
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.
Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.
An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.